FeesSafety
Pluang+

Rezolute's Phase 3 upLIFT study hits primary endpoint, showing strong results for tumor hyperinsulinism treatment.

Company Fundamentals
13 Nov 2026, 13:18 WIB
GlobeNewsWire
View Source
Bullish
Rezolute's Phase 3 upLIFT study hits primary endpoint, showing strong results for tumor hyperinsulinism treatment.

Rezolute announced positive preliminary results from its Phase 3 upLIFT study of ersodetug for tumor hyperinsulinism, achieving the primary efficacy endpoint with 13 of 16 patients reducing glucose infusion rate by at least 50%. This indicates a significant reduction in intravenous glucose dependency for hypoglycemia caused by tumors. The company expects full topline results by mid-December 2026 and plans to discuss FDA approval pathways in early 2027. Ersodetug, a monoclonal antibody, shows promise as a treatment for refractory hypoglycemia from various tumor types, addressing a critical unmet medical need.

Rezolute's Phase 3 upLIFT study results provide context for health-sector investors. For readers following health stocks, here is Pluang's market snapshot as of Nov 13, 2026 17:21 WIB: Out of 150 priced US health stocks, 89 rose and 52 fell. Notable movers include DYN at USD 17.35 (+2.00%), TVTX at USD 52.57 (+1.96%), and MRVI at USD 7.83 (+1.95%).

More News

Investec Bank Plc disclosed sale of 25,000 shares in Logistics Development Group on Nov 12, 2026.

Investec Bank Plc disclosed sale of 25,000 shares in Logistics Development Group on Nov 12, 2026.

Investec Bank Plc, acting as an exempt principal trader and advisor to DBAY Advisors Limited, disclosed the sale of 25,000 ordinary shares of Logistics Development Group Plc on November 12, 2026. The shares were sold at a price of 23 per unit. There ...

Market News
Neutral
40 minutes ago
Investec Bank discloses share dealings for Advanced Medical Solutions Group on Nov 12, 2026.

Investec Bank discloses share dealings for Advanced Medical Solutions Group on Nov 12, 2026.

Investec Bank Plc, acting as advisor and joint broker to Advanced Medical Solutions Group Plc, disclosed public dealings in the company's ordinary shares on November 12, 2026. The bank purchased 345,456 shares at prices between 282.561 and 283 pence ...

Market News
Neutral
49 minutes ago
Philippines solar market to hit 23.35 GW by 2032, growing at 27.46% CAGR driven by cheaper costs and corporate demand

Philippines solar market to hit 23.35 GW by 2032, growing at 27.46% CAGR driven by cheaper costs and corporate demand

The Philippines solar energy market is projected to grow from 5.43 GW in 2026 to 23.35 GW by 2032, with a CAGR of 27.46%. Growth is fueled by declining costs of solar panels and installation, government-backed renewable energy auctions, and increasin...

Market News
Bullish
1 hour ago
Equinor shares trade ex-dividend for Q2 2026 with a $0.39 payout starting Nov 13.

Equinor shares trade ex-dividend for Q2 2026 with a $0.39 payout starting Nov 13.

Equinor ASA shares will trade ex-dividend on the Oslo Stock Exchange starting November 13, 2026, for the second quarter of 2026. The declared dividend amount is $0.39 per share, payable in USD. This means investors buying shares from this date will n...

Company Fundamentals
Neutral
1 hour ago
China Eastern Airlines signs $540M procurement deals, unveils new aviation tech at CIIE

China Eastern Airlines signs $540M procurement deals, unveils new aviation tech at CIIE

China Eastern Airlines signed 23 procurement agreements worth $540 million with 15 suppliers from eight countries at the 9th China International Import Expo in Shanghai. The deals cover aircraft engines, aviation materials, jet fuel, and in-flight ca...

Bullish
2 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App